Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
The Norwegian Cancer Society have recently published a popular science article (in Norwegian) presenting the work of Gunhild Mælandsmo and Kjersti Flatmark, both from the Department of Tumor Biology at the Institute for Cancer Research. The scientists explains how their research on colorectal cancer may improve the methods of personalized medicine, and how the MetAction study, which is supported by the Norwegian Cancer Society, may contribute to the development of more precise cancer treatments in the future.
John Arne Dahl (photo), from Department of Microbiology has published a collaborative study entitled "Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition", in the 22nd September issue of Nature (journal impact factor 41.5).
The study was carried out together with the lab of Arne Klungland, Department of Microbiology, and Bing Ren, University of California and Ludwig Institute for Cancer Research, San Diego.
The findings are also covered in a news article on the web site of the Ludwig Institute for Cancer Research.
A comprehensive interview with postdoc Marina Vietri from Harald Stenmark's group at the Department of Molecular Biology has recently been published on ResearchItaly.it - the web portal of the Italian Ministry of Education, University and Research (MIUR) established in order to map, support and promote high-quality Italian research.
The introduction to the English version of this readable interview goes as follows: "From San Raffaele in Milan to the Institute for Cancer Research of the University Hospital of Oslo where her research deserved publication in Nature and she won the Norwegian H.M. the King’s Gold medal for best PhD thesis in Medicine in the year 2016, being the first Italian researcher who has ever received it."
A group at the Department of Immunology at OUH has developed software tools that help solving one of the biggest challenges in large-scale protein analysis, or proteomics. In an article published in prestigious Nature Methods (journal impact factor 32.1) they show that Microsoft Excel can be applied to align large datasets from multiple studies and obtain a better picture of how cells are wired.
POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis
A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G.Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
A small subgroup of patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading are shown to have excellent prognosis.
Molecular targeting of tumor hypoxia is a promising strategy for improving the radiotherapy of cervical cancer. A biomarker for classifying patients according to hypoxia is, however, lacking and is an important requirement for reliable drug evaluation and to avoid added toxicity to patients with no expected benefit.
In a study published in Clinical Cancer Research (journal impact factor 8.7), postdoc Christina S. Fjeldbo (photo) in Lyng’s group and colleagues at Oslo University Hospital and Aarhus University Hospital present a hypoxia classifier that is reflected in diagnostic DCE-MR images and based on the expression level of six genes in a biopsy.
The Norwegian Cancer Genomics Consortium participates in international study of gene variants predisposing for cancer development.
Norwegian Cancer Genomics Consortium (NCGC) consists of clinicians and specialised cancer research groups, situated at the Norwegian University Hospitals, and is led by professor Ola Myklebost (photo) from the Department of Tumor Biology at Oslo University Hospital.
The NCGC participates in an international study of gene variants predisposing for cancer development. Findings from the study has recently been published in Lancet Oncology (journal impact factor 24.69). The article - entitled "Monogenic and polygenic determinants of sarcoma risk: an international genetic study" has also got an editorial comment: "Are sarcomas hereditary?".
The Norwegian Cancer Society calls attention to collaborative study on relevance of genetic heterogeneity
The Norwegian Cancer Society has recently presented a research project on their home page where researchers from Oslo and Bergen have performed genetic analyses on cancer cells that have spread from the gut to the liver. The results show that the degree of genetic heterogenenity between the metastases to the liver may reveal important prognostic information.. The study led by Ragnhild A. Lothe from the Department of Moleceular Oncology at OUS and Per Eystein Lønning from Haukeland University Hospital.
Clinical relevance of genetic heterogeneity among distinct liver metastatic deposits identified in patients with colorectal cancer
In this collaborative study with Dept Oncology, Haukeland University Hospital and Dept Computer Science, University of Oslo, scientist Anita Sveen (photo) and colleagues in the Lothe group show that patients with a low level of heterogeneity, based on DNA copy number analyses of multiple metastases per patient, have a 4.6X and 3.6X longer three-year progression free and overall survival rate than patients with a high heterogeneity level.
The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2017.
The total funding available for this call is approximately 100 million Norwegian kroner.
Application deadline is Tuesday, September 6th 2016 kl. 16:00.
Dr. Bastian Fromm – Postdoc in Flatmark group
Sep 26, 2016
Histone marks regulate maternal-to-zygotic transition
Sep 15, 2016
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
Cellular Functions and Molecular Mechanisms of the ESCRT Membrane-Scission Machinery
Trends Biochem Sci (in press)
Germinal Center B Cell Dynamics
Immunity, 45 (3), 471-82
More selected publications